Clinical Trials Browser

OTHER × Interventional × cobimetinib × Clear all

NCT02693535 2026-05-29

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03202940 2026-05-08

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05441514 2026-05-05

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04409639 2026-04-24

CONCERTO

Phase 2 Active not recruiting

14 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT04216953 2026-04-23

COTESARC

Phase 1/2 Completed

Sarcoma

NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

NCT05034627 2025-11-28

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04079179 2025-09-18

NACHO-COBI

Phase 2 Recruiting

Histiocytosis, Langerhans-Cell, Xanthogranuloma, Juvenile, Histiocytosis, Sinus, Histiocytic Disorders, Malignant, Erdheim-Chester Disease, Histiocytic Sarcoma

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2 Completed

49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT02902029 2025-04-09

ImmunoCobiVem

Phase 2 Completed

Melanoma

NCT04722575 2025-03-13

NEO-TIM

Phase 2 Active not recruiting

Melanoma

NCT03224767 2025-02-18

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2 Active not recruiting

Craniopharyngioma

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis

NCT04214418 2024-12-18

MEKiAUTO

Phase 1/2 Terminated

27 enrolled 12 charts

Gastrointestinal

Gastrointestinal Neoplasms

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

5 enrolled 10 charts

Melanoma

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03430947 2023-09-14

RadioCoBRIM

Phase 2 Terminated

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

Neoplasms

NCT02414750 2022-11-30

REPOSIT

Phase 2 Terminated

Melanoma

NCT02036086 2022-10-27

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Phase 2 Unknown

Melanoma

NCT01959633 2022-02-24

VEMUPLINT

Phase 1/2 Completed

Melanoma

NCT02818023 2022-01-03

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Breast Neoplasms

NCT03224208 2021-04-26

VECODUE

Phase 2 Terminated

Melanoma

NCT02303951 2021-02-03

NEO-VC

Phase 2 Terminated

Melanoma

NCT02968303 2020-06-05

COWBOY

Phase 2 Unknown

Sarcoma, Clear Cell

NCT02583516 2020-02-17

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT02537600 2020-01-27

CONVERCE

Phase 2 Completed

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01813214 2019-02-26

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Phase 2 Terminated

5 enrolled 7 charts

Melanoma

NCT03340558 2018-10-09

ATELIER

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01876641 2018-09-19

ML28604

Phase 1 Terminated

Melanoma

NCT01495988 2017-10-24

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Phase 2 Terminated

10 enrolled 10 charts

Melanoma

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Phase 3 Withdrawn

Melanoma